RESUMO
Health systems around the world cope with the challenge of difficult economic times, and the value of health technology assessment (HTA) is increasing. Making the right choices, with limited resources, in the face of increasingly complex technologies requires decisions informed by data and analyses that help us to manage the risks involved. Those who undertake and use HTA can play a greater role in helping decision makers meet these challenges; they need to think how to define innovation and respond to it, how to communicate their analyses, and, critically, how to align their work with the ambitions of their health systems. HTA can become a key health system enabler without compromising its objectivity or independence. It can say that it is too early to determine the value of a new technology when the data simply will not support a safe decision. However, it can also be bold and recommend the managed introduction of new technologies, even when the when the data is immature, provided that the health system understands the risks and there is a plausible case for believing that further research will support the value proposition. The goal for HTA is to be able confidently to do both.
Assuntos
Comunicação , Idioma , Avaliação da Tecnologia Biomédica , EconomiaAssuntos
Antineoplásicos/economia , Tomada de Decisões/ética , Acessibilidade aos Serviços de Saúde/economia , Atenção Primária à Saúde/economia , Medicina Estatal/economia , Antineoplásicos/provisão & distribuição , Regulamentação Governamental , Acessibilidade aos Serviços de Saúde/normas , Humanos , Guias de Prática Clínica como Assunto , Atenção Primária à Saúde/normas , Reino UnidoRESUMO
Last week the National Institute for Clinical Excellence merged with the Health Development Agency, boosting the profile of an organisation that chief executive Andrew Dillon claims 'all three parties are keen to maintain' and which 26 per cent of the population has heard of. But is the newly expanded NICE ready--and able--to deliver on its public health remit?